Week in Review: Zai Lab Targets $1 Billion Valuation in Planned US IPO

02:22 EDT 13 Aug 2017 | ChinaBio Today

Deals and Financings
- Zai Lab has selected investment bankers for a US IPO with a rumored goal of raising $150 million at a $1 billion company valuation; 
- Hangzhou Just Biotherapeutics (Just China) completed a $57 million Series B funding to develop a portfolio of affordable innovative and biosimilar products;
- New Horizon Health, a Beijing-Hangzhou company developing early-stage cancer screening products, raised $20 million in a B round;
- Shanghai Fosun Pharma is competing with Shanghai Pharma Holding to acquire a $600-$700 million stake in Atlanta's Arbor Pharma;
- Biocept, a San Diego diagnostics company, completed a $2.2 million private placement from Ally Bridge, who will help the company with a China strategy;
- Shenzhen Salubris negotiated a tech transfer with the US National Institutes of Health for a potential liver cancer drug;
- HitGen of Chengdu began a multi-target, multi-year drug discovery collaboration with LEO Pharma A/S, a Danish dermatology company;
Company News
- Shanghai Pharma signed a MOU with DHL Supply Chain to prepare for a global expansion and optimize its current China pharma distribution network;
Trials and Approvals
-Dennis Lo, PhD, founder of Hong Kong cancer screening company Cirina, led a successful three-year test among 20,000 men for nasopharyngeal cancer, showing the value of early screening.

Stock Symbols: (SHA: 600196; HK: 2196) (SHA: 601607) (NSDQ: BIOC) (SZE: 2294)

Share this with colleagues:

Original Article: Week in Review: Zai Lab Targets $1 Billion Valuation in Planned US IPO


More From BioPortfolio on "Week in Review: Zai Lab Targets $1 Billion Valuation in Planned US IPO"

Quick Search

Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...